2.71%
34.02%
174.75%
125.67%
89.48%
37.55%
42.17%
AI Spotlight on CSBR
Company Description
Champions Oncology, Inc.develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis.
The company markets its products through internet, word of mouth, and sales force to patients and physicians.The company was formerly known as Champions Biotechnology, Inc.and changed its name to Champions Oncology, Inc.
in April 2011.Champions Oncology, Inc.was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Market Data
| Last Price | 10.99 |
| Change Percentage | 2.71% |
| Open | 10.59 |
| Previous Close | 10.7 |
| Market Cap ( Millions) | 152 |
| Volume | 43064 |
| Year High | 11.99 |
| Year Low | 3.6 |
| M A 50 | 7.29 |
| M A 200 | 5.33 |
Financial Ratios
| FCF Yield | -1.85% |
| Dividend Yield | 0.00% |
| ROE | 66.22% |
| Debt / Equity | 994.86% |
| Net Debt / EBIDTA | 280.40% |
| Price To Book | 219.38 |
| Price Earnings Ratio | -249.83 |
| Price To FCF | -53.93 |
| Price To sales | 2.84 |
| EV / EBITDA | 108.71 |
News
- Jan -08 - Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
- Dec -27 - Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies
- Dec -11 - Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript
- Dec -11 - Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
- Dec -05 - Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
- Oct -16 - Champions Oncology Announces Agreement with Weill Cornell Medicine
- Sep -12 - Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript
- Sep -11 - Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
- Sep -09 - Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
- Jul -18 - Champions Oncology Reports Quarterly Revenue of $14.0 Million
- Jul -11 - Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
- Jun -04 - Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
- Mar -12 - Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript
- Mar -12 - Champions Oncology Reports Quarterly Revenue of $12.0 Million
- Mar -07 - Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
- Mar -06 - Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
- Dec -12 - Champions Oncology, Inc. (CSBR) Q2 2024 Earnings Call Transcript
- Dec -12 - Champions Oncology Reports Quarterly Revenue of $11.6 Million
- Dec -04 - Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023
- Nov -02 - Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmacology Services
Expected Growth : 3 %
What the company do ?
Pharmacology Services from Champions Oncology, Inc. provide personalized oncology solutions, offering customized tumor models and efficacy testing to accelerate cancer drug development.
Why we expect these perspectives ?
Champions Oncology's Pharmacology Services growth is driven by increasing demand for personalized medicine, advancements in precision oncology, and rising adoption of biomarker-based drug development. Additionally, growing need for targeted therapies, expanding oncology pipeline, and strategic partnerships are contributing to the segment's growth.
Segment n°2 -> Other Translational Oncology Solutions
Expected Growth : 3 %
What the company do ?
Champions Oncology's Other Translational Oncology Solutions provide personalized tumor modeling, biomarker discovery, and immunotherapy development to accelerate cancer research and treatment.
Why we expect these perspectives ?
Champions Oncology's Other Translational Oncology Solutions segment growth is driven by increasing adoption of personalized medicine, rising demand for biomarker-based cancer diagnostics, and strategic partnerships with pharmaceutical companies to accelerate drug development. Additionally, advancements in immuno-oncology and targeted therapies are fueling growth in this segment.
Segment n°3 -> Personalized Oncology Services
Expected Growth : 3 %
What the company do ?
Champions Oncology's Personalized Oncology Services provide tailored cancer treatment plans using biomarker analysis and tumor profiling to identify effective therapies.
Why we expect these perspectives ?
Champions Oncology's Personalized Oncology Services growth is driven by increasing demand for precision medicine, advancements in genomics and immunotherapy, and a growing need for personalized treatment options. Additionally, the company's unique tumorgraft platform and comprehensive biomarker testing capabilities position it for continued growth.
Champions Oncology, Inc. Products
| Product Range | What is it ? |
|---|---|
| TumorGraft | A platform that develops and banks patient-derived xenograft (PDX) models from various types of cancer, allowing for personalized cancer treatment and research |
| AngioPred | A predictive analytics platform that uses artificial intelligence and machine learning to identify biomarkers for angiogenesis, a key factor in cancer progression |
| Champions TumorGraft Platform | A comprehensive platform that provides a suite of services, including PDX model development, biomarker discovery, and personalized medicine solutions |
| Personalized Oncology Solutions | A range of services that provide personalized cancer treatment plans, including biomarker analysis, genomic profiling, and PDX modeling |
Champions Oncology, Inc.'s Porter Forces
Threat Of Substitutes
Champions Oncology, Inc. has a moderate threat of substitutes due to the availability of alternative cancer treatment options, but the company's unique approach to personalized oncology and its strong research and development capabilities mitigate this threat.
Bargaining Power Of Customers
Champions Oncology, Inc. has a low bargaining power of customers due to the specialized nature of its services and the lack of alternative providers, giving the company significant pricing power.
Bargaining Power Of Suppliers
Champions Oncology, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for its research and development activities, but the company's reliance on a few key suppliers for certain materials and services limits its negotiating power.
Threat Of New Entrants
Champions Oncology, Inc. has a low threat of new entrants due to the high barriers to entry in the personalized oncology market, including the need for significant research and development investments and regulatory approvals.
Intensity Of Rivalry
Champions Oncology, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry, but the company's unique approach and strong research and development capabilities help it to differentiate itself from competitors.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 64.97% |
| Debt Cost | 3.95% |
| Equity Weight | 35.03% |
| Equity Cost | 5.92% |
| WACC | 4.64% |
| Leverage | 185.48% |
Champions Oncology, Inc. : Quality Control
Champions Oncology, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNTH | Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that … |
| TCRX | TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
| ONCT | Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal … |
| TARS | Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Dianthus Therapeutics
A-Score
1-Year Total Return ->
🥈
Kymera Therapeutics
A-Score
1-Year Total Return ->
🥉
Tarsus Pharmaceuticals
A-Score
1-Year Total Return ->
4
Champions Oncology
A-Score
1-Year Total Return ->
5
Oncternal Therapeutics
A-Score
1-Year Total Return ->
6
